SCHEMBL17522783

SCHEMBL17522783

CC(=O)c1ccc(F)c(OCCCCc2c(C)n[nH]c2C)c1

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 6/20 0.81
▸ ALB P02768 1/20 0.81
▸ HSD17B10 Q99714 7/20 0.53
▸ LMNA P02545 6/20 0.53
▸ MAPT P10636 6/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ HTT P42858 4/20 0.53
▸ TSHR P16473 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.48
▸ GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24953188 0.97 TTR (0.83) TTRALBHSD17B10LMNAMAPT
SCHEMBL15832081 0.92 TTR (0.95) TTRALBHSD17B10LMNAMAPT
Acoramidis SCHEMBL15816954 0.90 TTR (1.00) TTRALBHSD17B10LMNAMAPT
Acoramidis SCHEMBL29350324 0.90 TTR (1.00) TTRALBHSD17B10LMNAMAPT
SCHEMBL17522791 0.89 TTR (0.94) TTRALBHSD17B10LMNAMAPT
Acoramidis SCHEMBL20475239 0.89 TTR (0.98) TTRALBHSD17B10LMNAMAPT
Acoramidis SCHEMBL29390976 0.89 TTR (0.98) TTRALBHSD17B10LMNAMAPT
SCHEMBL17522792 0.87 TTR (0.69) TTRALBHSD17B10LMNAMAPT
SCHEMBL15816998 0.86 TTR (0.81) TTRALBHSD17B10LMNAMAPT
SCHEMBL15816962 0.85 TTR (1.00) TTRALBHSD17B10LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE MAHA THERAPEUTICS, INC. 2016-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE TTR, TTPA, SERPINA6 TTR 1/4885ALB 4/4885HSD17B10 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback